Mubadala Investment Co PJSC is 10% Owner at RECURSION PHARMACEUTICALS, INC. (RXRX). They have made 14 open-market trades across 4 companies since 2017, most recently 2025-07-29.
CIK 0001704268
11 open-market purchases totalling $129.5M since 2018, against 3 sales. Across 9 scored buys the stock is down 4.9% at ninety days, and 8.7 points behind the S&P over the same stretch.
9 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 11% | 0% | 67% |
| Avg Move | -6.2% | -14.6% | -4.9% |
| Alpha | -4.8% | -15.5% | -8.7% |
| Scored | 9 | 9 | 9 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PrivateMidCap Apollo Institutional Private Lending | BUY | 2025-07-29 | 2025-07-31 | $24.16 | $37.4M | N/A | N/A | N/A |
| PrivateMidCap Apollo Institutional Private Lending | BUY | 2024-06-14 | 2025-09-11 | $25.95 | $86.5M | N/A | N/A | N/A |
| RXRX | BUY | 2023-03-02 | 2023-03-03 | $7.82 | $1.0M | -12.0% | -18.9% | +3.2% |
| RXRX | BUY | 2023-03-01 | 2023-03-02 | $7.94 | $776K | -5.9% | -15.0% | +8.1% |
| RXRX | BUY | 2023-02-28 | 2023-03-01 | $7.97 | $6K | -3.0% | -15.7% | +11.5% |
| RXRX | BUY | 2023-02-27 | 2023-02-28 | $7.69 | $404K | -13.0% | -20.7% | +8.5% |
| RXRX | BUY | 2023-02-24 | 2023-02-27 | $7.64 | $1.7M | -5.9% | -15.3% | +10.7% |
| RXRX | BUY | 2023-02-17 | 2023-02-21 | $7.71 | $977K | +8.2% | -13.6% | +3.6% |
| RXRX | BUY | 2023-02-13 | 2023-02-14 | $7.97 | $518K | -7.3% | -8.2% | -32.8% |
| RXRX | BUY | 2023-02-01 | 2023-02-02 | $7.97 | $5K | -8.5% | -9.8% | -43.3% |
| AMD | SELL | 2019-02-05 | 2019-02-07 | $23.43 | $1.6B | +7.3% | +2.8% | +21.3% |
| GAIA | BUY | 2018-12-04 | 2019-05-14 | $12.74 | $194K | -8.3% | -14.3% | -13.5% |
| AMD | SELL | 2018-07-30 | 2018-08-01 | $19.33 | $850.5M | +8.6% | +38.5% | -5.3% |
| AMD | SELL | 2017-08-04 | 2017-08-04 | $52.56 | $2.1B | -5.3% | -3.1% | -18.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.